98%
921
2 minutes
20
Background: Extracellular vesicles secreted by tumor cells contain double-stranded DNA called extracellular vesicle DNA (evDNA). EvDNA is genomic DNA that reflects cancer driver mutations. However, the significance of evDNA analysis in the diagnosis and surveillance of colon cancer remains unclear. This study aimed to investigate the clinical utility of extracellular vesicles and evDNA isolated from the plasma of colon cancer patients harboring G12D and G13D mutations.
Methods: Cell-free DNA (cfDNA) and evDNA were collected from the plasma of 30 patients with colon cancer. mutation status (G12D and G13D) was detected using a droplet digital polymerase chain reaction assay (ddPCR). Sensitivity and specificity were evaluated in patients with wild-type tumors. Mutation status was correlated with carcinoembryonic antigen (CEA) levels and overall survival (OS).
Results: Thirty cfDNA and evDNA pairs showed a fractional abundance (FA) ranging from 0 to 45.26% and 0 to 83.81%, respectively. When compared with eight wild-type samples, cfDNA exhibited 70% sensitivity and 100% specificity, whereas evDNA achieved 76.67% sensitivity and 100% specificity. The concentration of evDNA was significantly lower than that of cfDNA, but it obtained a higher FA than cfDNA, while showing a positive correlation with CEA.
Conclusions: Our findings demonstrate the feasibility of evDNA as a complementary tool to aid current methods of patient evaluation in the diagnosis and surveillance of colon cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797818 | PMC |
http://dx.doi.org/10.3389/fonc.2022.1067210 | DOI Listing |
BJS Open
September 2025
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Background: Appendiceal adenocarcinomas and low-grade appendiceal mucinous neoplasms (LAMNs) are rare tumours. Much of the existing knowledge is derived from registry-based studies, particularly the Surveillance, Epidemiology, and End Results database in the USA.
Methods: This retrospective cohort study used data from the Swedish Cancer Registry, Swedish Cause of Death Registry, and the National Patient Registry to analyse demographic characteristics and outcomes of patients diagnosed with appendiceal adenocarcinoma or LAMN between 2005 and 2019.
Khirurgiia (Mosk)
September 2025
Saint Petersburg State University, Saint Petersburg, Russia.
Objective: To evaluate diagnostic significance of IL-6 compared to CRP for early detection of anastomotic leakage after colon resection for colorectal cancer.
Material And Methods: The study included 277 patients who underwent total resection for colorectal cancer. Patients were retrospectively divided into three groups: without complications (=227), with anastomotic leakage (=30), and other postoperative complications (=20).
Dis Colon Rectum
September 2025
Department of Surgery, Oregon Health & Science University, Portland, Oregon.
Background: Anal squamous cell cancer incidence has risen 2.2% each year over the past decade. Current screening includes anal cytology and high-resolution anoscopy but is burdened with sampling error and patient discomfort.
View Article and Find Full Text PDFCancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFAnn Gastroenterol Surg
September 2025
Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Aims: To determine the optimal extent of lymph node dissection for non-metastatic colon cancer by tumor location based on the therapeutic value index (TVI) for each lymph node station.
Methods: Consecutive patients with surgical stage I-III colon or rectosigmoid cancer in the Japanese Society for Cancer of the Colon and Rectum database who underwent curative resection between January 2003 and December 2014 were analyzed. The TVI was defined as the incidence of lymph node metastasis multiplied by 5-year overall survival and calculated for each nodal station stratified by tumor location.